{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:36:03Z","timestamp":1790789763630,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jiph.2023.05.010","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T12:50:35Z","timestamp":1683723035000},"page":"1048-1056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Revealing the structural and molecular interaction landscape of the favipiravir-RTP and SARS-CoV-2 RdRp complex through integrative bioinformatics: Insights for developing potent drugs targeting SARS-CoV-2 and other viruses"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3958-239X","authenticated-orcid":false,"given":"Chiranjib","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manojit","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abinit","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Alshammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metab","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Saikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9508-2712","authenticated-orcid":false,"given":"Soumen","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7469-4752","authenticated-orcid":false,"given":"Kuldeep","family":"Dhama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jiph.2023.05.010_bib1","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4103\/ijo.IJO_843_20","article-title":"COVID-19 pandemic: lessons learned and future directions","volume":"68","author":"Khanna","year":"2020","journal-title":"Indian J Ophthalmol"},{"issue":"6585","key":"10.1016\/j.jiph.2023.05.010_bib2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1126\/science.abn1900","article-title":"Stopping pandemics before they start: lessons learned from SARS-CoV-2","volume":"375","author":"Edwards","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jiph.2023.05.010_bib3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s43856-022-00175-8","article-title":"Leveraging lessons learned from the COVID-19 pandemic for HIV","volume":"2","author":"Calder","year":"2022","journal-title":"Commun Med"},{"issue":"7","key":"10.1016\/j.jiph.2023.05.010_bib4","first-page":"4016","article-title":"SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options","volume":"24","author":"Chakraborty","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.jiph.2023.05.010_bib5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.arcmed.2020.05.001","article-title":"Probable molecular mechanism of Remdesivir for the treatment of COVID-19: need to know more","volume":"51","author":"Saha","year":"2020","journal-title":"Arch Med Res"},{"key":"10.1016\/j.jiph.2023.05.010_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.704205","article-title":"The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: lessons learned from major clinical studies","volume":"12","author":"Chakraborty","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jiph.2023.05.010_bib7","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3389\/fphar.2020.01258","article-title":"Repurposing drugs, ongoing vaccine, and new therapeutic development initiatives against COVID-19","volume":"11","author":"Saha","year":"2020","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.jiph.2023.05.010_bib8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.arcmed.2020.05.009","article-title":"Tocilizumab: a therapeutic option for the treatment of cytokine storm syndrome in COVID-19","volume":"51","author":"Saha","year":"2020","journal-title":"Arch Med Res"},{"issue":"1","key":"10.1016\/j.jiph.2023.05.010_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jmv.26016","article-title":"Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia","volume":"93","author":"Mazzitelli","year":"2021","journal-title":"J Med Virol"},{"issue":"11","key":"10.1016\/j.jiph.2023.05.010_bib10","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/jmv.26078","article-title":"COVID-19: consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients","volume":"92","author":"Chakraborty","year":"2020","journal-title":"J Med Virol"},{"issue":"10","key":"10.1016\/j.jiph.2023.05.010_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10101612","article-title":"Therapeutic role of neutralizing antibody for the treatment against SARS-CoV-2 and its emerging variants: a clinical and pre-clinical perspective","volume":"10","author":"Bhattacharya","year":"2022","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.jiph.2023.05.010_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12967-020-02355-3","article-title":"SARS-CoV-2 RNA polymerase as target for antiviral therapy","volume":"18","author":"Buonaguro","year":"2020","journal-title":"J Transl Med"},{"key":"10.1016\/j.jiph.2023.05.010_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbrc.2020.08.116","article-title":"RNA-dependent RNA polymerase: structure, mechanism, and drug discovery for COVID-19","volume":"538","author":"Jiang","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.jiph.2023.05.010_bib14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/17512433.2021.1874348","article-title":"SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development","volume":"14","author":"Chakraborty","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jiph.2023.05.010_bib15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/cbic.202000595","article-title":"Tackling COVID-19 using remdesivir and favipiravir as therapeutic options","volume":"22","author":"Sreekanth Reddy","year":"2021","journal-title":"Chembiochem: a Eur J Chem Biol"},{"issue":"4","key":"10.1016\/j.jiph.2023.05.010_bib16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s42399-021-00824-4","article-title":"Remdesivir, favipiravir, and dexamethasone repurposed for COVID-19: a comprehensive clinical and pharmacovigilant reassessment","volume":"3","author":"Tocilizumab","year":"2021","journal-title":"SN Compr Clin Med"},{"issue":"4","key":"10.1016\/j.jiph.2023.05.010_bib17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","article-title":"Favipiravir: a new and emerging antiviral option in COVID-19","volume":"76","author":"Agrawal","year":"2020","journal-title":"Med J, Armed Forces India"},{"issue":"7","key":"10.1016\/j.jiph.2023.05.010_bib18","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1093\/jac\/dkaa171","article-title":"Favipiravir, an antiviral for COVID-19?","volume":"75","author":"Coomes","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2023.05.010_bib19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","article-title":"Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial","volume":"103","author":"Udwadia","year":"2021","journal-title":"Int J Infect Dis: IJID: Publ Int Soc Infect Dis"},{"issue":"11","key":"10.1016\/j.jiph.2023.05.010_bib20","first-page":"12575","article-title":"Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19","volume":"13","author":"Ruzhentsova","year":"2021","journal-title":"Am J Transl Res"},{"issue":"1","key":"10.1016\/j.jiph.2023.05.010_bib21","doi-asserted-by":"crossref","first-page":"11022","DOI":"10.1038\/s41598-021-90551-6","article-title":"The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials","volume":"11","author":"Hassanipour","year":"2021","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.jiph.2023.05.010_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01897-20","article-title":"A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19","volume":"64","author":"Doi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jiph.2023.05.010_bib23","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1186\/s13054-020-03288-5","article-title":"Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series","volume":"24","author":"Fu","year":"2020","journal-title":"Crit Care"},{"issue":"2","key":"10.1016\/j.jiph.2023.05.010_bib24","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir Res"},{"key":"10.1016\/j.jiph.2023.05.010_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jiph.2023.05.010_bib26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.coph.2021.07.020","article-title":"Therapeutics development for Ebola virus disease: a recent scenario","volume":"60","author":"Chakraborty","year":"2021","journal-title":"Curr Opin Pharmacol"},{"issue":"9","key":"10.1016\/j.jiph.2023.05.010_bib27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4103\/1995-7645.267581","article-title":"Ebola virus disease: recent advances in diagnostics and therapeutics. Asian Pacific","volume":"12","author":"Jagga","year":"2019","journal-title":"Asian Pac J Trop Med"},{"issue":"3","key":"10.1016\/j.jiph.2023.05.010_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLOS Med"},{"issue":"7","key":"10.1016\/j.jiph.2023.05.010_bib29","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser B, Phys Biol Sci"},{"key":"10.1016\/j.jiph.2023.05.010_bib30","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/978-1-4939-7000-1_26","article-title":"Protein data bank (PDB): the single global macromolecular structure archive","volume":"1607","author":"Burley","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.jiph.2023.05.010_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10822-010-9395-8","article-title":"Computer-aided drug design platform using PyMOL","volume":"25","author":"Lill","year":"2011","journal-title":"J Comput-Aided Mol Des"},{"issue":"2","key":"10.1016\/j.jiph.2023.05.010_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/protein\/8.2.127","article-title":"LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions","volume":"8","author":"Wallace","year":"1995","journal-title":"Protein Eng"},{"issue":"10","key":"10.1016\/j.jiph.2023.05.010_bib33","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1021\/ci200227u","article-title":"LigPlot+: multiple ligand-protein interaction diagrams for drug discovery","volume":"51","author":"Laskowski","year":"2011","journal-title":"J Chem Inf Model"},{"issue":"1","key":"10.1016\/j.jiph.2023.05.010_bib34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/pro.3289","article-title":"PDBsum: structural summaries of PDB entries","volume":"27","author":"Laskowski","year":"2018","journal-title":"Protein Sci"},{"issue":"W1","key":"10.1016\/j.jiph.2023.05.010_bib35","doi-asserted-by":"crossref","first-page":"W368","DOI":"10.1093\/nar\/gky309","article-title":"MOLEonline: a web-based tool for analyzing channels, tunnels and pores (2018 update)","volume":"46","author":"Pravda","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"10.1016\/j.jiph.2023.05.010_bib36","doi-asserted-by":"crossref","first-page":"W374","DOI":"10.1093\/nar\/gkx385","article-title":"DynOmics: dynamics of structural proteome and beyond","volume":"45","author":"Li","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"10.1016\/j.jiph.2023.05.010_bib37","doi-asserted-by":"crossref","first-page":"W272","DOI":"10.1093\/nar\/gkac348","article-title":"DrugVirus.info 2.0: an integrative data portal for broad-spectrum antivirals (BSA) and BSA-containing drug combinations (BCCs)","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"10.1016\/j.jiph.2023.05.010_bib38","doi-asserted-by":"crossref","first-page":"D1288","DOI":"10.1093\/nar\/gkac813","article-title":"DrugMAP: molecular atlas and pharma-information of all drugs","volume":"51","author":"Li","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.jiph.2023.05.010_bib39","article-title":"Structural basis of SARS-CoV-2 polymerase inhibition by favipiravir","volume":"2","author":"Peng","year":"2021","journal-title":"Innovation"},{"issue":"7","key":"10.1016\/j.jiph.2023.05.010_bib40","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021946118","article-title":"Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP","volume":"118","author":"Naydenova","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.jiph.2023.05.010_bib41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir","volume":"12","author":"Kokic","year":"2021","journal-title":"Nat Commun"},{"issue":"6498","key":"10.1016\/j.jiph.2023.05.010_bib42","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.jiph.2023.05.010_bib43","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.molcel.2021.01.035","article-title":"Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication","volume":"81","author":"Bravo","year":"2021","journal-title":"Mol Cell"},{"issue":"3","key":"10.1016\/j.jiph.2023.05.010_bib44","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.01051-06","article-title":"Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice","volume":"51","author":"Sidwell","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jiph.2023.05.010_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLOS Med"},{"issue":"5","key":"10.1016\/j.jiph.2023.05.010_bib46","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/cid\/cix406","article-title":"Favipiravir and ribavirin treatment of epidemiologically linked cases of lassa fever","volume":"65","author":"Raabe","year":"2017","journal-title":"Clin Infect Dis: Publ Infect Dis Soc Am"},{"issue":"22","key":"10.1016\/j.jiph.2023.05.010_bib47","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1056\/NEJMc1806941","article-title":"Mutagenesis in norovirus in response to favipiravir treatment","volume":"379","author":"Ruis","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2023.05.010_bib48","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.coph.2021.07.020","article-title":"Therapeutics development for Ebola virus disease: a recent scenario","volume":"60","author":"Chakraborty","year":"2021","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jiph.2023.05.010_bib49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.coph.2021.10.006","article-title":"Editorial overview: an initiative toward Ebolavirus disease (EVD) free world: an edited special anti-infective issue on Ebola virus disease","volume":"62","author":"Ohimain","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jiph.2023.05.010_bib50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40249-016-0105-1","article-title":"Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus","volume":"5","author":"Karthick","year":"2016","journal-title":"Infect Dis Poverty"},{"issue":"15","key":"10.1016\/j.jiph.2023.05.010_bib51","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1503\/cmaj.114-0074","article-title":"Ebola eradication may need wider partnership","volume":"186","author":"Agoramoorthy","year":"2014","journal-title":"CMAJ: Can Med Assoc J = J De l'Assoc Med Can"},{"issue":"20","key":"10.1016\/j.jiph.2023.05.010_bib52","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.jiph.2023.05.010_bib53","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/cid\/cix406","article-title":"Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever","volume":"65","author":"Raabe","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"22","key":"10.1016\/j.jiph.2023.05.010_bib54","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1056\/NEJMc1806941","article-title":"Mutagenesis in norovirus in response to favipiravir treatment","volume":"379","author":"Ruis","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jiph.2023.05.010_bib55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4149\/av_2017_01_48","article-title":"T-705 (Favipiravir) suppresses tumor necrosis factor alpha production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug","volume":"61","author":"Tanaka","year":"2017","journal-title":"Acta Virol"},{"issue":"4","key":"10.1016\/j.jiph.2023.05.010_bib56","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.bbrc.2012.07.034","article-title":"Favipiravir (T-705) inhibits in vitro norovirus replication","volume":"424","author":"Rocha-Pereira","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.jiph.2023.05.010_bib57","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1073\/pnas.0909603107","article-title":"T-705 (favipiravir) activity against lethal H5N1 influenza A viruses","volume":"107","author":"Kiso","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.jiph.2023.05.010_bib58","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1128\/AAC.01156-16","article-title":"Distinct effects of T-705 (Favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis","volume":"60","author":"Vanderlinden","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"18","key":"10.1016\/j.jiph.2023.05.010_bib59","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/1873-3468.14182","article-title":"Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination","volume":"595","author":"Padhi","year":"2021","journal-title":"FEBS Lett"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034123001661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034123001661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:17:07Z","timestamp":1761751027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034123001661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1876034123001661"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2023.05.010","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revealing the structural and molecular interaction landscape of the favipiravir-RTP and SARS-CoV-2 RdRp complex through integrative bioinformatics: Insights for developing potent drugs targeting SARS-CoV-2 and other viruses","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2023.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}